Heparin pretreatment for STEMI primary angioplasty: a meta-analysis

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• The optimal timing for unfractionated heparin (UFH) administration in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary angioplasty remains debated.
• Current clinical guidelines allow physician discretion regarding pre-angioplasty UFH timing.

Purpose of the Study:

• To evaluate the impact of early unfractionated heparin (UFH) pretreatment on outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
• To assess the association of UFH pretreatment with TIMI flow and 30-day mortality in STEMI patients.

Main Methods:

• A systematic search of PubMed and Cochrane databases was performed for studies comparing UFH pre-treatment versus no UFH in STEMI patients undergoing primary angioplasty.
• A meta-analysis of 7 studies (36,831 patients) was conducted, assessing TIMI flow and 30-day mortality, with publication bias analysis.

Main Results:

• UFH pre-treatment was associated with a significantly higher probability of achieving TIMI grade II/III flow (HR, 1.35; 95% CI, 1.25-1.45; P < .0001).
• Patients receiving UFH pre-treatment had a lower 30-day mortality rate (HR, 0.80; 95% CI, 0.72-0.90; P = .0002).
• No significant difference in bleeding complications was observed between the UFH pre-treatment and control groups (HR, 0.87; 95% CI, 0.72-1.05; P = .150).

Conclusions:

• Pretreatment with unfractionated heparin in STEMI patients undergoing primary angioplasty is linked to improved coronary blood flow and reduced early mortality.
• The findings support the consideration of early UFH administration in STEMI patients undergoing primary angioplasty.